Abstract
The only definitive therapy for patients with pheochromocytoma is surgical resection [1,2**]. Advances in preoperative medical management of hypertension/hypovolemia and improved intraoperative anesthetic care have reduced the operative mortality rate for pheochromocytoma to less than 5% in most series. In addition, accurate preoperative localization studies have eliminated the need for extensive exploratory laparotomy. Focused approach and laparoscopic resection have become the new "gold standard," with a reduced morbidity [4**]. Large or locally invasive pheochromocytomas may still require open resection.
MeSH terms
-
3-Iodobenzylguanidine / therapeutic use
-
Adrenal Gland Neoplasms* / complications
-
Adrenal Gland Neoplasms* / diagnosis
-
Adrenal Gland Neoplasms* / metabolism
-
Adrenal Gland Neoplasms* / therapy
-
Adrenal Medulla / metabolism
-
Adrenalectomy / methods
-
Adrenergic alpha-Antagonists / therapeutic use
-
Antihypertensive Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Catecholamines / metabolism
-
Catecholamines / urine
-
Diagnostic Imaging
-
Humans
-
Hypertension / drug therapy
-
Hypertension / etiology
-
Laparoscopy
-
Metanephrine / urine
-
Neoplastic Syndromes, Hereditary
-
Palliative Care
-
Pheochromocytoma* / complications
-
Pheochromocytoma* / diagnosis
-
Pheochromocytoma* / metabolism
-
Pheochromocytoma* / therapy
-
Tachycardia / drug therapy
-
Tachycardia / etiology
Substances
-
Adrenergic alpha-Antagonists
-
Antihypertensive Agents
-
Catecholamines
-
3-Iodobenzylguanidine
-
Metanephrine